Zobrazeno 1 - 10 of 36 pro vyhledávání: '"Jeong-Hyeok Yoon"'
1
Abstract 1627: PHI-501, a novel and potent pan-RAF inhibitor in metastatic melanoma
Autor: Namkyeong Kim, Jung Hee Park, Ky-Youb Nam, June H-J Han, Kyu-Tae Kim, Sandip Sengupta, Jeong Hyeok Yoon, Taebo Sim
Publikováno v: Cancer Research. 83:1627-1627
Background: PHI-501 has been developed as a novel inhibitor of NRAS mutated acute myeloid leukemia. Big data and artificial intelligence (AI)-based drug discovery platform and cell-based investigation identified PHI-501 repurposable against melanoma
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::042c73ad2983f6d85826d8fe72119d93
https://doi.org/10.1158/1538-7445.am2023-1627
Zobrazit plný text záznamu
2
Abstract 411: PHI-501, a novel pan-RAF/DDRs dual kinase inhibitor, overcomes BRAF or MEK inhibitor resistance in melanoma
Autor: Sue Min Kim, Jung Hee Park, Ky-Youb Nam, June H-J Han, Kyu-Tae Kim, Jeong Hyeok Yoon, Sandip Sengupta, Taebo Sim, Sang Joon Shin
Publikováno v: Cancer Research. 83:411-411
Background: PHI-501 is a newly developed, highly effective, and orally accessible dual inhibitor for pan-RAF and discoidin domain receptor (DDR) that is a collagen-activated receptor tyrosine kinase. Mutations of the BRAF and NRAS are the most common
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::9878f8f217c74cd66ce0f0273bb5ba91
https://doi.org/10.1158/1538-7445.am2023-411
Zobrazit plný text záznamu
4
Abstract 5495: PHI-501, a potent and novel inhibitor of NRAS mutated acute myeloid leukemia
Autor: Ky-Youb Nam, Jung Hee Park, Kyung Ah Kim, Inje Shin, June H-J Han, Kyu-Tae Kim, Jeong Hyeok Yoon, Hanna Cho, Seung-Hye Choi, Sandip Sengupta, Taebo Sim
Publikováno v: Cancer Research. 82:5495-5495
Purpose: Development of the first-in-class inhibitor of NRAS mutated acute myeloid leukemia. PHI-501 has potent activity against receptor tyrosine kinases and intracellular kinases related to STAT, AKT, and ERK signaling. Description: Preclinical tes
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::b7493949cf8b1960a8f6e2e9d7ec7e54
https://doi.org/10.1158/1538-7445.am2022-5495
Zobrazit plný text záznamu
5
Hot spot profiles of SARS-CoV-2 and human ACE2 receptor protein protein interaction obtained by density functional tight binding fragment molecular orbital method
Autor: Hocheol Lim, Jongwan Kim, Jiaxin Liu, Kyoung Tai No, Ky Youb Nam, Jeong Hyeok Yoon, Min Sung Kim, Ayoung Baek
Publikováno v: Scientific Reports, Vol 10, Iss 1, Pp 1-8 (2020)
Scientific Reports
The prevalence of a novel β-coronavirus (SARS-CoV-2) was declared as a public health emergency of international concern on 30 January 2020 and a global pandemic on 11 March 2020 by WHO. The spike glycoprotein of SARS-CoV-2 is regarded as a key targe
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8db7007f37e3a6eacbe61bb223553ce1
https://doi.org/10.1038/s41598-020-73820-8
Zobrazit plný text záznamu
6
A Phase 1a/1b First in Human Study of PHI-101, a Potent Small Molecule Inhibitor of FLT3 in Relapsed and Refractory Acute Myeloid Leukemia
Autor: Bao Nguyen, Jeong-Hyeok Yoon, Yunsuk Choi, Joseph Clarey, Ky-Youb Nam, Ho-Jin Shin, Jeong Ok Lee, Anish Puliyayil, Jeejin Im, Jun Ho Jang, Kyu-Tae Kim, Dong-Yeop Shin, Sung-Soo Yoon, June-Won Cheong, June H-J. Han, Je-Hwan Lee, Donald Small, Li Li
Publikováno v: Blood. 138:3425-3425
Background: The FMS-like tyrosine kinase 3 (FLT3) is mutated in approximately 30% of acute myeloid leukemia (AML) patients either by internal tandem duplication (ITD) or by point mutations in the tyrosine kinase domain (TKD). PHI-101 is a Type I FLT3
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::95111f71a6f086e9e28f12c912afc2bc
https://doi.org/10.1182/blood-2021-149395
Zobrazit plný text záznamu
7
Abstract 1461: PHI-101, a potent and novel inhibitor of CHK2 in ovarian and breast cancer cells
Autor: Kyu-Tae Kim, Jeejin Im, Min Kyung Choi, Ky-Youb Nam, Jeong-Hyeok Yoon, Inki Kim, Sojung Park, June H-J. Han
Publikováno v: Cancer Research. 81:1461-1461
Purpose: Development of the potent and selective checkpoint kinase 2 (CHK2) inhibitor to overcome limiting clinical utility of poly(ADP-ribose) polymerase 1 (PARP1) inhibitors. Experimental Procedure: Preclinical evaluation of PHI-101 for cellular an
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::3898f453eaf7939f8070d580bbb23aba
https://doi.org/10.1158/1538-7445.am2021-1461
Zobrazit plný text záznamu
8
Investigation of protein-protein interactions and hot spot region between PD-1 and PD-L1 by fragment molecular orbital method
Autor: Jongwan Kim, Hocheol Lim, Xuemei Jin, Kyoung Tai No, Jungho Chun, Jeong Hyeok Yoon
Publikováno v: Scientific Reports
Scientific Reports, Vol 9, Iss 1, Pp 1-11 (2019)
Inhibitors to interfere protein-protein interactions (PPI) between programmed cell death 1 (PD-1) and programmed death ligand-1 (PD-L1) block evasion of cancers from immune surveillance. Analyzing hot spot residues in PPI is important for small-molec
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e0b4a7f106b7c173e5bbf3741e29ecca
http://europepmc.org/articles/PMC6853875
Zobrazit plný text záznamu
9
PHI-101 Is a Potent Third-Generation FLT3 Inhibitor Developed to Overcome Resistance in Acute Myeloid Leukemia
Autor: Jeejin Im, Jeong-Hyeok Yoon, Kyu-Tae Kim, Cho Han Na, Taebo Sim, Seung-Hye Choi, Ruiqi Zhu, Li Li, Ky-Youb Nam, June H-J H-J Han, Donald Small, David J. Young, Bao Nguyen
Publikováno v: Blood. 136:28-28
Background: FMS-like tyrosine kinase 3 (FLT3), a member of the class III receptor tyrosine kinase family, plays a pivotal role in regulating cell growth and differentiation of hematopoietic cells. FLT3 is mutated in approximately 30% of AML patients
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::53b492670a0334d3f0274f7342729023
https://doi.org/10.1182/blood-2020-139044
Zobrazit plný text záznamu
10
Abstract 4226: PHI-101, a next generation FLT3 inhibitor for acute myeloid leukemia
Autor: Jeejin Im, Ruiqi Zhu, Li Li, Ky-Youb Nam, Jeong-Hyeok Yoon, Donald Small, David J. Young, Bao Nguyen
Publikováno v: Cancer Research. 80:4226-4226
Purpose: Develop a next generation FLT3 TKI to overcome previous resistance mechanisms. Description: Preclinical testing of PHI-101 for efficacy against FLT3 mutations both in vitro and in vivo in cell lines and primary FLT3 mutant leukemia samples.
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::695c8540d5a90717ef6e1100e7878379
https://doi.org/10.1158/1538-7445.am2020-4226
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje